Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma

Hartmann, Tim; Hübel, Kai; Monsef, Ina; Engert, Andreas; Skoetz, Nicole

doi:10.1002/14651858.cd010615.pub2

Cited by 21 publications

(19 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…4, 5, 17 To utilize the benefit of plerixafor, our institutional algorithm is to give individuals with clinical characteristics suggesting a high risk of mobilization failure preemptive day 4 plerixafor. We and others have defined high risk of mobilization as patients who received radiation, ≥10 cycles of chemotherapy, or ≥ age 60.…”

Section: Discussionmentioning

confidence: 99%

A single center’s experience using four different front line mobilization strategies in lymphoma patients planned to undergo autologous hematopoietic cell transplantation

Haverkos¹,

Huang

Elder

et al. 2017

Bone Marrow Transplant

View full text Add to dashboard Cite

In an otherwise eligible patient with relapsed lymphoma, inadequate mobilization of peripheral blood stem cells is a limiting factor to proceeding with an autologous hematopoietic cell transplantation (auto-HCT). Multiple strategies have been used to mobilize an adequate number of hematopoietic stem cells (HSCs) with no obvious front-line strategy. We report a single institutional experience mobilizing HSCs using four different approaches in lymphoma patients. We prospectively collected mobilization outcomes on patients planning to undergo auto-HCT at Ohio State University. We report results of first mobilization attempt for all relapsed or refractory lymphoma patients between 2008–2014. We identified 255 lymphoma patients who underwent mobilization for planned auto-HCT. The 255 lymphoma patients underwent the following front line mobilization strategies: 95 (37%) GCSF alone, 38 (15%) chemomobilization (GCSF+chemotherapy), 97 (38%) preemptive day 4 plerixafor, and 25 (10%) rescue day 5 plerixafor. As expected, there were significant differences between cohorts including age, comorbid indices, histology, and amount of prior chemotherapy. After controlling for differences between groups, the odds of collecting 2×106/kg HSCs on the first day of collection and 5×106/kg HSCs in total was highest in the cohort undergoing chemomobilization. In conclusion, our experience highlights the effectiveness of chemomobilization.

show abstract

Section: Discussionmentioning

confidence: 99%

A single center’s experience using four different front line mobilization strategies in lymphoma patients planned to undergo autologous hematopoietic cell transplantation

Haverkos¹,

Huang

Elder

et al. 2017

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…These and other observations strongly suggest SDF-1/CXCR4 signaling as promising target in anti-cancer therapy, in particular, in combination with radiation therapy (3). However, clinical development of CXCR4 antagonists has mainly focussed on mobilization of hematopoietic stem cells from the bone marrow to peripheral blood (4).…”

Section: Introductionmentioning

confidence: 99%

Potential Role of CXCR4 Targeting in the Context of Radiotherapy and Immunotherapy of Cancer

Schilbach²,

et al. 2018

View full text Add to dashboard Cite

Cancer immunotherapy has been established as standard of care in different tumor entities. After the first reports on synergistic effects with radiotherapy and the induction of abscopal effects—tumor shrinkage outside the irradiated volume attributed to immunological effects of radiotherapy—several treatment combinations have been evaluated. Different immunotherapy strategies (e.g., immune checkpoint inhibition, vaccination, cytokine based therapies) have been combined with local tumor irradiation in preclinical models. Clinical trials are ongoing in different cancer entities with a broad range of immunotherapeutics and radiation schedules. SDF-1 (CXCL12)/CXCR4 signaling has been described to play a major role in tumor biology, especially in hypoxia adaptation, metastasis and migration. Local tumor irradiation is a known inducer of SDF-1 expression and release. CXCR4 also plays a major role in immunological processes. CXCR4 antagonists have been approved for the use of hematopoietic stem cell mobilization from the bone marrow. In addition, several groups reported an influence of the SDF-1/CXCR4 axis on intratumoral immune cell subsets and anti-tumor immune response. The aim of this review is to merge the knowledge on the role of SDF-1/CXCR4 in tumor biology, radiotherapy and immunotherapy of cancer and in combinatorial approaches.

show abstract

“…A number of literature reviews describing the role of plerixafor in HSC mobilization have been published (2,9,10). However, to date, and at least to the best of our knowledge, level-1 evidence in the form of a systematic review and meta-analysis has been conducted only once (11). The published review analyses data from the first 2 randomized controlled trials (RCTs) were conducted by DiPersio et al in 2009 (12,13).…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of plerixafor for hematopoietic stem cell mobilization for autologous transplantation in patients with non‑Hodgkin lymphoma and multiple myeloma: A systematic review and meta‑analysis

et al. 2019

View full text Add to dashboard Cite

Plerixafor in combination granulocyte-colony stimulating factor (G-CSF) has been used for the mobilization of hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM). The aim of this study was to systematically search the published literature and analyze evidence on the efficacy of additional plerixafor for successful HSC mobilization in patients with NHL and MM, and to evaluate the safety of the drug. The PubMed, Scopus, Cochrane Central Register of Controlled Trials (CENTRAL) and Google scholar databases were searched electronically for studies published in the English language up to March, 2019. Five studies (3 on NHL and 2 on MM) were included in this review article. The meta-analysis of data of 364 patients in the treatment group and 368 patients in the control group, indicated that the mobilization of ≥5/6×10 6 CD34 + cells/kg in 4 or less apheresis days was superior with plerixafor + G-CSF than with G-CSF alone (RR=2.59, 95% CI: 1.40 to 4.81; P<0.0001). Similarly, a greater proportion of patients in the treatment group exhibited the mobilization of ≥2×10 6 CD34 + cells/kg in 4 or less apheresis days (RR=1.46, 95% CI: 1.01 to 2.12; P=0.04). The addition of plerixafor significantly increased the total collection of CD34 + cells (random: MD=4.21; 95% CI: 2.85 to 5.57; P<0.00001). Meta-analysis indicated no significant increase in adverse events with the addition of plerixafor for HSC mobilization (RR=1.03, 95% CI: 0.99 to 1.06; P=0.16). On the whole, the findings of this study indicate that the addition of plerixafor to G-CSF leads to an increased HSC collection in a shorter period of time with no concomitant increase in adverse events. Further randomized controlled trials with a larger sample size evaluating short term efficacy, as well as long term survival would help to further strengthen the evidence on this subject.

show abstract

Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma

Cited by 21 publications

References 46 publications

A single center’s experience using four different front line mobilization strategies in lymphoma patients planned to undergo autologous hematopoietic cell transplantation

A single center’s experience using four different front line mobilization strategies in lymphoma patients planned to undergo autologous hematopoietic cell transplantation

Potential Role of CXCR4 Targeting in the Context of Radiotherapy and Immunotherapy of Cancer

Efficacy and safety of plerixafor for hematopoietic stem cell mobilization for autologous transplantation in patients with non‑Hodgkin lymphoma and multiple myeloma: A systematic review and meta‑analysis

Contact Info

Product

Resources

About